Shares of biotech company 10x Genomics (NASDAQ:TXG ... Revenue declined by 10% year on year, reflecting ongoing weakness in demand, particularly in instrument sales, though consumables performed ...

Get access to 10+ additional ProTips and comprehensive valuation metrics with InvestingPro's detailed research report. In other recent news, 10X Genomics announced preliminary fourth-quarter sales ...

10x Genomics has prioritized technological advancement, introducing products that strive to deliver cost-effective and versatile solutions to researchers. This includes instruments like the GEM-X ...

Genomics (NASDAQ:TXG – Get Free Report) had its price target reduced by investment analysts at Citigroup from $20.00 to $15.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage ...

10x Genomics' instruments sales fell to $24.35 million from $38.4 million a year ago. This included $10.93 million from Chromium instruments and $13.43 million from Spatial instruments.

Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT ... Plate-based workflows for Chromium GEM-X Flex: The company announced plans for plate-based GEM-X Flex ...

Potential delays in adoption for new products like Visium HD and GEM-X. Macroeconomic uncertainties could impact spending in academia and biopharma. 10x Genomics delivered strong Q4 2023 results ...